CD163 and neoplasm: For PFS analysis, residual tumor disease (HR: 1.97, CI: 1.23–3.16, p = 0.005) and the presence of CD68+ CLSs (HR: 2.11, CI: 1.23–3.64, p = 0.007) in model 1 and the presence of CD163+ CLSs (HR: 2.02, CI: 1.17–3.48, p = 0.012) in model 2 were significantly associated with worse PFS.